Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
| dc.rights.license | open | en_US |
| dc.contributor.author | LEMAITRE, Florian | |
| dc.contributor.author | GREGOIRE, Matthieu | |
| dc.contributor.author | MONCHAUD, Caroline | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BOUCHET, Stephane | |
| dc.contributor.author | SAINT-SALVI, Beatrice | |
| dc.contributor.author | POLARD, Elisabeth | |
| dc.date.accessioned | 2022-06-10T08:55:36Z | |
| dc.date.available | 2022-06-10T08:55:36Z | |
| dc.date.issued | 2022-04-20 | |
| dc.identifier.issn | 1958-5578 (Electronic) 0040-5957 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/140183 | |
| dc.description.abstractEn | OBJECTIVES: Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral agent targeting the 3-chymotrypsin-like cysteine protease enzyme (3C-like protease or Mpro) which is a key enzyme of the viral cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This combination with a well-known pharmacokinetic enhancer leads to a high risk for drug-drug interactions in a polymedicated elected population for treatment. The aim of this work was to provide recommendations on behalf of the national French society of pharmacology (French Society of Pharmacology and Therapeutics; SFPT), by suggesting optimal and pragmatic therapeutic strategies if nirmatrelvir/ritonavir is to be given together with drugs commonly used, in order to ensure secured physicians' prescription. METHODS: Six clinical pharmacologists search the scientific literature to provide a first draft of recommendations. Thereafter, twelve other clinical pharmacologists verified the recommendations and proposed modifications. The final draft was then validated by all 18 participants. RESULTS: Five distinct recommendations were issued: i) contra-indications, ii) "PAXLOVID™ not recommended with the comedication", iii) "PAXLOVID™ possible whether the comedication is discontinued", iv) "PAXLOVID™ possible only after an expert advice" and v) "PAXLOVID™ possible without modification of the associated treatment". The final document comprises recommendations for 171 drugs/therapeutic classes aiming to secure prescription. In complex situations, clinicians are advised to contact their pharmacology department to obtain specific recommendations on the management of drug-drug interactions with nirmatrelvir/ritonavir. CONCLUSION: These recommendations intend to be a help for clinicians willing to prescribe nirmatrelvir/ritonavir and to prevent drug-drug interactions leading to adverse drug reactions or loss of efficacy. They constitute a guideline for primary care situations. Of course, some complex situations may require expert advices and here, again, clinical pharmacologists are at the forefront in providing therapeutic advice. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Paxlovid | |
| dc.subject.en | Antiviral | |
| dc.subject.en | Ritonavir | |
| dc.subject.en | Drug monitoring | |
| dc.subject.en | Pharmacokinetics | |
| dc.subject.en | Pharmacodynamics | |
| dc.title.en | Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.therap.2022.03.005 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35618549 | en_US |
| bordeaux.journal | Thérapie | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Th%C3%A9rapie&rft.date=2022-04-20&rft.eissn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.issn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.au=LEMAITRE,%20Florian&GREGOIRE,%20Matthieu&MONCHAUD,%20Caroline&BOUCHET,%20Stephane&SAINT-SALVI,%20Beatrice&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||